Articles
-
3 days ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 While the CGT sector has made significant strides in oncology, its transformative potential extends well beyond cancer. A growing number of companies are advancing CGT approaches for rare and inherited diseases, including those affecting vision.
-
2 weeks ago |
cellandgene.com | Erin Harris
Discover the future of iPSC-based therapies in this free Cell & Gene Live digital event. Experts will share insights on emerging applications, regulatory challenges, gene editing advancements, and key safety considerations in scalable iPSC manufacturing. Don't miss this opportunity to hear from leaders at the forefront of regenerative medicine. Supported by Invetech.
-
3 weeks ago |
cellandgene.com | Erin Harris |Dan Nelson |CARR Biosystems |Royce Tourtillott
Setting the Standard in CGT: Perspectives on Performance, Scalability, and Regulatory ComplianceExplore the evolving landscape of cell and gene therapy with insights from key opinion leaders. This white paper addresses challenges in process development and manufacturing across different modalities. Discover how end-to-end solutions can accelerate commercialization by prioritizing performance and scalability while simplifying the path to regulatory approvals.
-
3 weeks ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 In today’s turbulent biotech landscape, companies are being forced to rethink their strategies across every stage of development. Recently, I had the opportunity to sit down with Dr. Ali Pashazadeh, Founder of Treehill Partners, for a conversation in which he offered a candid and informed perspective on the financial pressures facing the CGT space and the strategic pivots that could help biotechs move forward.
-
1 month ago |
cellandgene.com | Erin Harris
By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 960
- Tweets
- 1K
- DMs Open
- No
RT @_CellandGene: On #CellAndGenePodcast, @ArrowheadPharma CMO Javier San Martin shares the roadmap for #RNAi as well as the company's pipe…
RT @_CellandGene: CGT manufacturers that deprioritize cybersecurity efforts risk their ecosystem being vulnerable to cyber-attacks that can…
RT @_CellandGene: Walter Strapps, CEO of @Carver_Bio states that when it comes to #mRNA, the challenges associated with its delivery are an…